Neil Berinstein

Title: Neil Berinstein: Innovator in Immunogenic Polypeptides

Introduction

Neil Berinstein is a notable inventor based in Toronto, Canada. He has made significant contributions to the field of immunology, particularly through his innovative work on immunogenic polypeptides. His research focuses on the development of agents that can elicit specific immune responses, which has important implications for cancer treatment.

Latest Patents

Neil Berinstein holds a patent for "Immunogenic polypeptides encoded by MAGE minigenes and uses thereof." This invention discloses immunogenic polypeptides that comprise several MAGE-specific antigen epitopes selected from different members of the MAGE protein family. The patent also includes nucleic acids coding for these polypeptides, recombinant viruses, and cells that incorporate these nucleic acids. Additionally, it outlines methods for eliciting or inducing MAGE-specific immune responses using the aforementioned immunogenic agents.

Career Highlights

Throughout his career, Neil Berinstein has worked with prominent organizations in the field of biotechnology and pharmaceuticals. Notably, he has been associated with Sanofi Pasteur Inc. and the Ludwig Institute for Cancer Research Limited. His work in these institutions has allowed him to advance his research and contribute to the development of innovative therapeutic solutions.

Collaborations

Neil has collaborated with esteemed colleagues, including James Tartaglia and John A. Tine. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his research in the scientific community.

Conclusion

Neil Berinstein's contributions to the field of immunology through his innovative patents and collaborations highlight his role as a significant inventor. His work continues to influence the development of new therapeutic strategies for cancer treatment.